Abstract：
Probiotics are viable microorganisms, which if delivered in appropriate dose can provide health benefits. Lactobacillus reuteri (DM17938+ATCC PTA 5289) has been recommended as a safe choice for probiotics. The objective of this study is to compare the improvement in the periodontal parameters amongst smokers with generalized periodontitis with Stage III, Grade C treated with nonsurgical periodontal treatment (NSPT) to which either an antibiotics or probiotics were given as an adjuvant.
Sixty smokers with Stage III, Grade C generalized periodontitis were randomized in two groups after taking informed consent. Periodontal parameters including bleeding on probing (BOP), probing depth (PD), attachment loss (AL), gingival index (GI), and plaque index (PI) were recorded. Group 1 received (after NSPT and oral hygiene instructions) amoxicillin and metronidazole for 7 days and a placebo for probiotics for 30 days. Group 2 was provided (after NSPT and oral hygiene instructions) with one tablet of Lactobacillus reuteri probiotics (2 × 108 CFU) twice daily for 30 days and placebo antibiotics for 7 days. The periodontal parameters were recorded again at 1- and 3-month follow-ups as outcome variables. Mean, standard deviation, and confidence interval were reported using SPSS 20.0.
A statistically significant clinical improvement in the PD, BOP, PI, and GI were observed in both the groups at 3-month follow-up. However, the AL remained unchanged in both the groups.
Administration of probiotics and antibiotics along with NSPT yield statistically significant differences in PD and BOP from baseline to 3-month follow-up. However, between the group differences were not statistically significant for the periodontal parameters (AL, PD, and BOP).
Sixty smokers with Stage III, Grade C generalized periodontitis were randomized in two groups after taking informed consent. Periodontal parameters including bleeding on probing (BOP), probing depth (PD), attachment loss (AL), gingival index (GI), and plaque index (PI) were recorded. Group 1 received (after NSPT and oral hygiene instructions) amoxicillin and metronidazole for 7 days and a placebo for probiotics for 30 days. Group 2 was provided (after NSPT and oral hygiene instructions) with one tablet of Lactobacillus reuteri probiotics (2 × 108 CFU) twice daily for 30 days and placebo antibiotics for 7 days. The periodontal parameters were recorded again at 1- and 3-month follow-ups as outcome variables. Mean, standard deviation, and confidence interval were reported using SPSS 20.0.
A statistically significant clinical improvement in the PD, BOP, PI, and GI were observed in both the groups at 3-month follow-up. However, the AL remained unchanged in both the groups.
Administration of probiotics and antibiotics along with NSPT yield statistically significant differences in PD and BOP from baseline to 3-month follow-up. However, between the group differences were not statistically significant for the periodontal parameters (AL, PD, and BOP).
摘要：
背景：益生菌是活的微生物，如果以适当的剂量给药，可以提供健康益处。罗伊氏乳杆菌(DM17938+ATCC+PTA5289)已被推荐作为益生菌的安全选择。这项研究的目的是比较患有广泛性牙周炎的吸烟者与III期的牙周参数的改善情况，用非手术牙周治疗（NSPT）治疗的C级，其中抗生素或益生菌作为佐剂。
方法：60名III期吸烟者，在知情同意后，将C级广泛性牙周炎随机分为两组。牙周参数包括探查出血（BOP），探测深度(PD),附着损失(AL)，牙龈指数（GI），记录菌斑指数(PI)。第1组(在NSPT和口腔卫生指导之后)接受阿莫西林和甲硝唑7天,以及接受益生菌安慰剂30天。第2组(在NSPT和口腔卫生说明之后)每天两次提供一片罗伊氏乳杆菌益生菌(2×108CFU),持续30天,以及安慰剂抗生素,持续7天。在随访1个月和3个月时再次记录牙周参数作为结果变量。意思是,使用SPSS20.0报告标准偏差和置信区间.
结果：PD有统计学意义的临床改善，防喷器,PI,随访3个月时，两组均观察胃肠道和胃肠道。然而,两组的AL保持不变。
结论：从基线到3个月随访，益生菌和抗生素与NSPT的施用在PD和BOP方面具有统计学上的显着差异。然而,组间牙周参数差异无统计学意义(AL，PD,和防喷器）。本文受版权保护。保留所有权利。
方法：60名III期吸烟者，在知情同意后，将C级广泛性牙周炎随机分为两组。牙周参数包括探查出血（BOP），探测深度(PD),附着损失(AL)，牙龈指数（GI），记录菌斑指数(PI)。第1组(在NSPT和口腔卫生指导之后)接受阿莫西林和甲硝唑7天,以及接受益生菌安慰剂30天。第2组(在NSPT和口腔卫生说明之后)每天两次提供一片罗伊氏乳杆菌益生菌(2×108CFU),持续30天,以及安慰剂抗生素,持续7天。在随访1个月和3个月时再次记录牙周参数作为结果变量。意思是,使用SPSS20.0报告标准偏差和置信区间.
结果：PD有统计学意义的临床改善，防喷器,PI,随访3个月时，两组均观察胃肠道和胃肠道。然而,两组的AL保持不变。
结论：从基线到3个月随访，益生菌和抗生素与NSPT的施用在PD和BOP方面具有统计学上的显着差异。然而,组间牙周参数差异无统计学意义(AL，PD,和防喷器）。本文受版权保护。保留所有权利。
